News

Article

FDA Approved Besponsa for Children With Acute Lymphoblastic Leukemia

Author(s):

Alex Biese,Brielle Benyon

The Food and Drug Administration approved Besponsa for pediatric patients aged 1 and older with relapsed or refractory CD22-positive, B-cell precursor ALL.

The Food and Drug Administration (FDA) has approved Besponsa (inotuzumab ozogamicin) for pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL), the agency has announced.

The efficacy of Besponsa was determined in a multicenter, single-arm, open-label study with 53 pediatric patients 1 year old and older with relapsed or refractory CD22-positive B-cell precursor ALL, according to the agency, which noted that the study evaluated two dose levels: an initial dose of 1.4 mg/m2/cycle in 12 patients and 1.8 mg/m2/cycle in 41 patients, with premedications including methylprednisolone 1 mg/kg (maximum of 50 mg), an antipyretic and an antihistamine, and patients receiving a median of 2 cycles of therapy.

Twenty-two of the 53 patents, or 42%, achieved complete response, indicating that their disease completely disappeared, with a median duration of complete response being 8.2 months.

Additionally, minimal residual disease (MRD)-negative complete response, defined as 5% or less blasts found in the bone marrow and no cancer found in the peripheral blood, occurred in 21 of 22 patients (95.5%) who had a complete response, based on flow cytometry, and 19 of 22 (86.4%) based on RQ-PCR, which is a test of the blood and bone marrow.

Besponsa was initially approved by the FDA in 2017 for the treatment of adults with relapsed or refractory ALL. According to the drug’s website, Besponsa is an antibody drug conjugate that works by targeting and binding to CD22, which is a protein found on many B-cell ALL cells. It then is internalized by the cancer cell and releases the cancer-killing component.

The most common side effects from Besponsa that occurred in 20% or more of patients were thrombocytopenia, fever, anemia, vomiting, infection, hemorrhage, neutropenia, nausea, leukopenia, febrile neutropenia, increased transaminases, abdominal pain and headache.


For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Image of a man with brown hair.
Image of a woman with short brown hair and glasses.
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Related Content
Image of woman with brown hair.
November 19th 2024

Newer Therapies for Acute Lymphoblastic Leukemia May Reduce Side Effects

Spencer Feldman Darlene Dobkowski, MA
New treatments for acute lymphoblastic leukemia may lead to fewer side effects than chemotherapy, as they target cancer cells more precisely, an expert said.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of blood.
November 15th 2024

FDA Approves Danziten for Leukemia Subset That Does Not Require Fasting

Darlene Dobkowski, MA
Danziten, a new formulation of nilotinib, may improve treatment adherence in patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of an adult holding a small child's hand in the hospital.
November 9th 2024

The Decision to Irradiate or Not to Irradiate My Daughter’s Brain Tumor

Mark Younce
My daughter's diagnosis of a rare and aggressive brain tumor at 3 years old made me strongly consider whether or not to have her treated with radiation.
Image of an orange background with the words "FDA Approval, developing story."
November 8th 2024

FDA Approves CAR-T Cell Therapy for Relapsed or Refractory B-Cell ALL

Darlene Dobkowski, MA
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based on findings from the FELIX trial.